Pharma Mar SAU (MC:PHMR) recently announced that Zepsyre® failed to show a progression-free survival (PFS) benefit over Topotecan and pegylated liposomal doxorubicin (PLD) in the 443-patient CORAIL study in platinum-resistant ovarian cancer. Zepsyre is currently in a Phase III trial in small cell lung cancer (SCLC) patients with protocols for pivotal studies in endometrial and breast cancer being finalised.
Phase III CORAIL study missed the primary endpoint
The 443-patient CORAIL study in platinum-resistant ovarian cancer missed the PFS primary endpoint. Details are scarce, although the company acknowledged that PFS for Zepsyre, Topotecan and PLD were the same (indicating that the drug does have single agent activity, just not enough to show a benefit over the standard of care). On a positive note, the company did disclose that Zepsyre demonstrated a better safety profile than the control arm, which is important for its programmes in other cancers.
To read the entire report Please click on the pdf File Below: